Accurate measurement and reduction of Scope 3 emissions will make or break biopharma sustainability efforts. But only 17% of biopharma companies are confident in their ability to accurately measure Scope 3 emissions. With 63% of biopharma companies reporting a belief that sustainability progress is imperative to business growth, we unpack the challenges confronting productive change in environmental sustainability despite focused interest and attention across the biopharma industry.
In this session, hear from stakeholders across the value chain to understand how the industry is making collective strides to set targets, measure, track, and reduce Scope 3 emissions more effectively; through supplier collaboration, integrated eco-design, and creative innovation across the value chain.
What you will learn:
- Key highlights from the 2024 Biopharma Sustainability Review – where the industry is putting its efforts into sustainability progress, and where there are opportunities for improvement
- Expert recommendations on how stakeholders across biopharma, government, and academia can work together to improve on areas of weakness and make progress together for the good of the planet